#ASH20: As Bristol Myers awaits FDA word, the CAR-T BCMA leaders go head-to-head once again. This time, they're not alone

Jason Mast

Editor

In 2017, when Nanjing’s Legend Biotech first parachuted onto ASCO with stunning BCMA CAR-T data, bluebird bio, the incumbents in the field, immediately criticized their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH20: As Bristol Myers awaits FDA word, the CAR-T BCMA leaders go head-to-head once again. This time, they're not alone

Jason Mast

Editor

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

#ASH20: As Bris­tol My­ers awaits FDA word, the CAR-T BC­MA lead­ers go head-to-head once again. This time, they're not alone

Jason Mast

Editor

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

#ASH20: As Bristol Myers awaits FDA word, the CAR-T BCMA leaders go head-to-head once again. This time, they're not alone

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?